| | | |  | | | | By Bob Herman BRENDAN SMIALOWSKI/AFP/GettyImages A new study finds health insurers paid drastically different prices for common cancer therapies at top cancer hospitals. Read More | | By Angus Chen A. Walker, L. Sharp & J. Pryde./Wellcome Collection Researchers presented data on an experimental vaccine that they hope will protect cancer and other immunocompromised patients from Covid. Read More | | By Adam Feuerstein Cel-Sci has not publicly discussed its intent to issue a data press release or to post new data on ClinicalTrials.gov this week. Read More | | Sponsor content by Legend Biotech Commercializing cell therapy: launching "disruptive" technologies requires innovative strategies Personalized medicine is changing the therapeutic landscape for patients and providers, but creating "disruptive" and highly individualized therapies requires a new approach to commercialization.
Steve Gavel, vice president of global commercial development at Legend Biotech, details how Legend, which was incorporated less than a decade ago, created the infrastructure to bring cell therapies to market at an accelerated speed. Read about its approach to commercialization and how it hopes a three-pronged strategy can ensure success. | | By Adam Feuerstein Kirsty Wigglesworth/AP The deal was struck three months after Sierra’s lead drug, a treatment for the blood cancer myelofibrosis, succeeded in a late-stage trial. Read More | | By Angus Chen Courtesy Kristin Anderson The work, while very early, pushes at the boundary of what might be possible – and practical – to do in immunotherapy. Read More | |
No comments